News
RT + ADT linked with improved survival in mPC
Key clinical point: The addition of radiotherapy (RT) to androgen deprivation therapy (ADT) was associated with improved survival in men with...
News
In-person, telephone genetic counseling yield similar outcomes
Key clinical point: Telephone genetic counseling was noninferior to in-person counseling for women at increased risk of hereditary breast and/or...
News
Early results promising for pembrolizumab in combination regimens for NSCLC
Key clinical point: Overall response rates ranged from 30% to 71% when pembrolizumab was added to chemotherapy combinations or paired with an R2...
News
Better pembrolizumab outcomes with increasing PD-L1 in NSCLC
Key clinical point: Pembrolizumab is superior to docetaxel in patients with non–small cell lung cancer especially at higher TPS. PD-L1 may be a...
News
Study results differ on benefits of proton radiotherapy in NSCLC
Key clinical point: Results of a small randomized trial and an analysis of the National Cancer Data Base show conflicting results about the...
News
Heat shock protein peptide vaccine appears safe, effective for glioblastoma patients
Key clinical point: A heat shock protein peptide vaccine appears safe and effective for patients with glioblastoma in an early stage trial. Major...
News
Neoadjuvant chemo for advanced ovarian cancer opens ‘window of opportunity’ for immunotherapies
Key clinical point: Neoadjuvant chemotherapy alters the immune microenvironment in patients with advanced ovarian cancer. Major finding:...
News
Vandetanib shows variable response, toxicity in RET-positive NSCLC
Key clinical point: Vandetanib shows marked yet variable anti-tumor activity and toxicity in patients with RET-rearranged NSCLC. Major finding:...
News
Cancer drugs most affordable in Australia, least in India and China
Key clinical point: Taking into account a country’s wealth and cost of living, cancer drugs are most affordable in Australia, least affordable in...
News
Novel antibody drug conjugate shows promise in SCLC
Key clinical point: Rova-T is active in DLL3-expressing recurrent and refractory small–cell lung cancer. Major finding: The clinical benefit rate...
News
Biosimilar trastuzumab comparable on safety, efficacy
Key clinical point: MYL-1401O is comparable in safety and efficacy to trastuzumab for women with HER2-positive advanced breast cancer. Major...
News
Early results positive for treating high-grade gliomas with virus-based therapy
Key clinical point: A phase I trial indicates that Toca 511 is safe and shows activity in treating patients with high-grade or recurrent...